TRACON Pharma Q2 EPS $(0.20) Beats $(0.36) Estimate, Sales $9.00M
Portfolio Pulse from bharat@benzinga.com
TRACON Pharma reported Q2 losses of $0.20 per share, beating the analyst consensus estimate of $0.36 by 44.44%. This is a 35.48% increase over losses from the same period last year. The company also reported $9.00 million in sales this quarter.
August 14, 2023 | 8:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TRACON Pharma's Q2 earnings beat analyst estimates by 44.44%, with a 35.48% increase over losses from the same period last year. The company also reported $9.00 million in sales.
TRACON Pharma's better-than-expected Q2 earnings and increased sales could lead to a positive short-term impact on its stock price. The company's performance exceeded analyst estimates, which is typically well-received by the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100